Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | FABP3 | P05413 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30063027 | 1.00 | LMNA (0.53) | LMNAPKMFFAR4FFAR1NPC1 | |
| SCHEMBL13506327 | 0.83 | LMNA (0.56) | LMNAFFAR4NPC1RAB9AKDM4E | |
| SCHEMBL2728131 | 0.83 | LMNA (0.64) | LMNANPC1RAB9AKDM4EMEN1 | |
| SCHEMBL18728131 | 0.81 | MRGPRX4 (0.55) | LMNAFFAR4NPC1RAB9AKDM4E | |
| SCHEMBL25166114 | 0.81 | LMNA (0.53) | LMNAPKMFFAR4FFAR1NPC1 | |
| SCHEMBL31507773 | 0.79 | NPC1 (0.38) | PKMNPC1RAB9AKDM4EMEN1 | |
| SCHEMBL25382184 | 0.77 | LMNA (0.41) | LMNAPKMFFAR4FFAR1L3MBTL1 | |
| SCHEMBL25384506 | 0.76 | HTR7 (0.40) | LMNANPC1RAB9AKDM4EMEN1 | |
| SCHEMBL28912822 | 0.76 | RAB9A (0.41) | LMNANPC1RAB9AKDM4EMEN1 | |
| SCHEMBL1264964 | 0.76 | LMNA (0.64) | LMNANPC1RAB9AKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12226405-B2 | Compounds and compositions for inhibiting the activity of HIF2-alpha and their methods of use | NOVARTIS AG (CH) | 2025-02-18 | — | — | US | disclosed |
| EP-4143187-B1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-ALPHA AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2024-05-08 | — | — | EP | disclosed |
| EP-4143187-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-ALPHA AND THEIR METHODS OF USE | Novartis AG (CH) | 2023-03-08 | — | — | EP | disclosed |
| US-20220401422-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-alpha AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2022-12-22 | — | — | US | disclosed |
| US-20220401422-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-alpha AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2022-12-22 | — | — | US | disclosed |
| CN-115485275-A | Compounds and compositions that inhibit HIF 2-alpha activity and methods of use thereof | 诺华股份有限公司 | 2022-12-16 | — | — | CN | disclosed |
| WO-2021217508-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2α AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021220170-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-ALPHA AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12226405-B2 | Compounds and compositions for inhibiting the activity of HIF2-alpha and their methods of use | HIF1AN, HIF1A, EGLN2 | LMNA 1575/4885PKM 455/4885FFAR4 3206/4885 |
| US-20220401422-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-alpha AND THEIR METHODS OF USE | HIF1AN, HIF1A, EGLN2 | LMNA 1575/4885PKM 455/4885FFAR4 3206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.